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Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an RNA virus which 
belongs to the family Arteriviridae. Since its emergence in the late 1980’s and early 1990’s, 
PRRSV has had a major economic effect on the swine industry. The most notable effects of this 
disease are respiratory distress in piglets and late-term pregnancy failures in sows. To track and 
control spread of this disease, the industry must be able determine which animals have been 
naturally infected with PRRSV as this contributes to major disease outbreaks and localized 
pandemics. While vaccines help control the spread of a disease, they also interfere with 
tracking of disease outbreaks. A DIVA test allows for the differentiation of animals which were 
naturally infected from those that were infected via immunization and is used in conjunction 
with a vaccine. Our primary objective was to develop rabbit polyclonal and mouse monoclonal 
antibodies against a highly immunogenic, heterologous gene not native to PRRSV to be used as 
reagents for a PRRSV specific DIVA (Differentiating Infected from Vaccinated Animals) test. To 
start the project, non-structural protein PRRSV-NSP2 was modified to include an immune 
marker (S-tag genetic marker) to be used as a positive selection tag that allows for the 
diagnostic detection of the vaccine virus strain. This protein was cloned into a plasmid 
expression vector, expressed in E. coli bacteria, and purified in order to be used as an antigen to 
immunize mice and rabbits. The immunization of rabbits was effective for producing polyclonal 
antibodies to be used for further research and diagnostic purposes, while the immunization of 
the mice was used to generate monoclonal antibodies through the formation of hybridoma 
cells. A hybridoma is produced by fusing splenic B cells from the immunized mice with mouse 
tumor cells (NS-1 myeloma). These hybridomas produced monoclonal antibodies which were 
expected to be specific to PRRSV MLVΔ23-S tag epitopes. These monoclonal antibodies were 
characterized and their ability to recognize PRRSV MLVΔ23-S tag epitopes was assessed via 
enzyme linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and Western 
blot assay. Overall, we recovered eighteen separate hybridoma cell lines which were 
immunoreactive via ELISA and Western blotting. Eight of these were also immunoreactive via 
IFA. We also obtained approximately 75 mL of anti-PRRSV S-tag specific rabbit polyclonal 
antisera. These resulting monoclonal and polyclonal antibodies will be useful to develop a DIVA 
test for the veterinary diagnostic industry. This test can be used to monitor the effectiveness of 
the PRRSV vaccine and spread of the disease in order to assist in reducing the major economic 
impact of PRRSV on the swine industry.  
 
Introduction 
 Porcine reproductive and respiratory syndrome virus (PRRSV), discovered in the United 
States in 1987, is a single-stranded, positive-sense RNA virus from the family Arteriviridae [1]. 
Its genome contains a minimum of 10 open reading frames (ORFs). ORF 1a and ORF 1b make up 
¾ of the viral genome and produce 14 non-structural proteins after enzymatic cleavage while 
ORFs 2-7 code for structural proteins (Figure 1) [2]. This disease causes respiratory distress in 
piglets and late-term pregnancy failures. It can be transmitted through direct contact with 
placental and intranasal membranes and replicates in regional macrophages, which then 
spreads throughout the body and causes viremia and infection of other macrophages [1]. This 
disease is economically devastating to the swine industry, even more so than diseases that 
previously impacted it. PRRSV is estimated to cost the swine industry around 560 million dollars 
annually compared to classical swine fever (364 million) and pseudorabies virus (36 million). 
This loss is due to a significant reduction in the number of piglets which survive to weaning as 
well as an increase in secondary infections, reduction in growth efficiency, and even death in 
growing-finishing pigs [3]. The substantial economic effects of PRRSV necessitate a need for 
improved technologies to study and manage the disease’s effects in order to move closer to the 













Figure 1. Organization of porcine reproduction and respiratory syndrome virus (PRRSV) genome. 
ORF1a and 1b code for 14 non-structural proteins, including our protein of interest: non-structural 




An important tool used in the eradication of disease is vaccines, which can be incredibly 
useful to decrease or even prevent infection for many diseases. The eradication of a disease 
also relies on comprehensive and accurate serological surveillance of that disease within a 
population. However, vaccinations can hinder serological surveillance of a disease as many 
vaccines induce an identical antibody response to that of natural infection. This issue can be 
resolved through the development and usage of a DIVA vaccine [4][5]. A DIVA vaccine is 
accompanied by a diagnostic test which allows the veterinary industry to determine which 
animals were naturally infected versus those that received a vaccine consisting of a modified 
live virus. This is useful for continued epidemiological investigation of PRRSV among the porcine 
population, and also enables continuous monitoring of the safety and success of the vaccine 
[6].   
The first step in the development of a DIVA test is to develop diagnostic detection 
reagents. Our primary objective was to develop rabbit polyclonal and mouse monoclonal 
antibodies against a highly immunogenic, heterologous gene not native to PRRSV to be used as 
reagents for a PRRSV specific DIVA test. To develop the monoclonal antibodies necessary for a 
DIVA test, we created hybridomas which produce monoclonal antibodies against PRRSV 
MLVΔ23-S tag protein [7].  A common method used to generate a DIVA vaccine and test is to 
take a protein from a virus and delete a portion of it, otherwise known as a negative selection 
marker [8]. Our technique differs from typical methods as we inserted an immune marker (an 
mRNA sequence that codes for a 15 amino acid S-tag genetic marker peptide sequence), known 
as a positive selection tag, into the genome of the PRRSV-NSP2 protein (Figure 1). The genetic 
sequence was then cloned into an expression vector which allowed it to be transformed in E. 
coli bacteria. The bacteria produced the S- tag protein which was then purified & used as 
antigen for immunization of mice and rabbits. After a 68-day immunization regimen, we 
harvested splenic B-cells from mice and fused them with NS-1 myeloma cells to form 
hybridomas which produced our monoclonal antibodies.  
Monoclonal antibodies are monovalent antibodies which are derived from a single B-
lymphocyte and have specific affinity for the same epitope. The most effective way to obtain 
these antibodies is by using a technique involving hybridoma formation [9]. Hybridomas were 
first successfully formed and used for monoclonal antibody production in 1975 by George 
Kohler and Cesar Milstein [10]. The process of forming a hybridoma starts with the 
immunization of a species with the antigen of interest. The B-lymphocytes from the immunized 
animal are then harvested from its spleen and fused with an immortal myeloma cell line. The 
myeloma cells lack the Hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene [9]. 
HGPRT is expressed when the hybridomas are placed in selective medium. This medium 
contains hypoxanthine-aminopterin-thymidine (HAT), which blocks unfused myeloma cells from 
using their salvage pathway to produce nucleotides due to their missing HGPRT gene. However, 
the myeloma cells which fused with B-cell inherit the HGPRT gene from the B-cells and are able 
to use it to produce pyrimidine nucleotides. The result of using this process is that only the 
hybridomas survive [11].  
Initially, the culture of hybridomas contains a variety of B-lymphocytes, each producing 
antibodies for different antigens. This provides a polyclonal mixture of antibodies. In order to 
isolate the desired monoclonal antibody, the hybridomas are diluted into a multi-well culture 
plate. This allows a greater likelihood that each well will contain a monoclonal hybridoma. Each 
well is then screened individually to determine if it contains antibodies specific to the target 
antigen. The positive wells are then recloned and undergo secondary screening to ensure they 
still have specificity for the antigen. The hybridomas can then be expanded to produce an 
abundance of monoclonal antibodies [9]. 
Monoclonal antibodies can be utilized in many ways. Most applicable to our research is 
their use in diagnostic tests, specifically indirect immunofluorescence assay (IFA), enzyme-
linked immunosorbent assay (ELISA), and Western blot. For an IFA, mammalian cells are 
transfected with DNA for the target antigen. The antibodies are put on the cells along with a 
fluorescent dye where they bind transfected cells. This allows the visualization of these cells 
using a fluorescent microscope. Instead of using DNA like in the IFA, an ELISA uses proteins. A 
specific protein from the target pathogen is attached to the surface of a plate and then 
antibodies specific to that protein are applied. These antibodies bind the protein. Next, a 
secondary antibody which is linked to an enzyme is plated which binds the primary antibody. 
Finally, a reagent containing the substrate specific to the enzyme on the secondary antibody is 
plated which results in a measurable color change. A Western blot assay is performed by first 
running a linear protein on a gel using electrophoresis. Next, primary antibodies are added to 
the gel which bind to the protein. Enzyme-conjugated secondary antibodies are added to the 
membrane next which bind to the primary antibodies and can be visualized via a color change 
imparted by the addition of a chromogenic substrate [12]. Using monoclonal antibodies in the 
context of IFA, ELISA, and Western blot allows us to evaluate the immunoreactivity of the 
antibodies which will then be used to validate a DIVA test for PRRSV.  
 
 
Materials and Methods 
Expression of the PRRSV NSP2 S-tag protein 
The 660-nucleotide codon optimized region of the PRRSV NSP2 genome which 
contained the S-tag gene was cloned into an expression vector (pET-28a, Novagen; Madison, 
WI) and then transformed into E. coli (BL21-Codon Plus DE3 RP competent) for expression of 
the protein. 50 μL of the transformed cells were plated onto agar plates and incubated at 37°C 
overnight. The next day, colonies were placed in 2X yeast extract tryptone (YT) culture media. 
Once the cultures were grown to an optical density of 0.5 at 37°C, then expression was induced 
using a 1.0 mM concentration of isopropyl β-D-1-thiogalactopyranoside (IPTG). This induced 
transcription of the Lac operon and the downstream NSP2 protein. The E. coli were incubated 
for an addition 8 hours at 37°C [12]. 
After the additional incubation, the bacteria were strained out and centrifuged at 
10,000 x g for 10 minutes at 4°C to obtain a pellet. Resuspension of the pellet was achieved 
using 50 mL of lysis buffer solution (B-PER, Pierce, Rockford, IL) which was then incubated at 
room temperature (20°C) for 20 minutes. It was then centrifuged at 10,000 x g to separate 
soluble and insoluble proteins. The protein was denatured with 8 M urea and purified using 
nickel-NTA affinity column chromatography. Elutions were collected, confirmed using SDS-
PAGE, then frozen at -80°C. Western blotting using a 6X histidine specific monoclonal antibody 
(Novagen; Madison, WI) was used in order to confirm the protein. The resulting NSP2 S-tag 
protein was used to immunize mice and rabbits [12].  
 
 
Development of enzyme-linked immunosorbent assay for hybridoma screening 
 An Immulon 1B medium binding 96 well micro-titer plate was coated with PRRSV NSP2 
S-tag protein and a heterologous HIS-tag control (SVS VP2 12-15-15). PRRSV NSP2 S-tag was 
diluted 1:2000 in antigen coating buffer (ACB) and 100 μL was added to odd numbered wells. 
SVS VP2 12-15-15 was also diluted 1:1500 in ACB and 100 μL was added to even numbered 
wells. The plate was allowed to incubate at 37°C for 1 hour. A 5% nonfat dry milk (Shurefine; 
Skukie, IL) and PBS solution was made as a blocking antibody diluent buffer (BAD) and 200 μL 
was applied to each well. This was incubated at 4°C overnight. In the morning, the plate was 
washed four times with PBS + 0.05% Tween 20 (PBST).  
 To screen the hybridomas, 60 μL of undiluted cell culture supernatant was added to 
each well. This was incubated for 1 hour at room temperature and then the plate washed four 
times with PBST. 100 μL of a goat anti-mouse, IgG, IgA, IgM-HRP conjugate (MP-Bio; Santa Ana, 
CA) diluted 1:5000 in BAD was added to each well and the plate was incubated for 1 hour at 
room temperature. TMB chromogenic substrate (VMRD; Whitman Country, WA) was removed 
from the fridge and allowed to warm to room temperature. It was then tested via a 1:150 
dilution of the enzyme-containing secondary and displayed a clear blue color indicating that it 
worked. The plate was washed four times in PBST and then 100 μL of TMB was added to each 
well. Finally, the reaction was stopped using 100 μL of 2N H2SO4 in each well and the optical 
densities were measured using an ELx800 microplate reader (BioTek Instruments Inc.; 
Winooski, VT) at 450 nm.  
 
 
Development of Western blot for hybridoma screening 
 Color chromogen development Western blotting was used to identify the PRRSV NSP2 S-
tag protein. For this method, the PRRSV NSP2 S-tag antigen was diluted 1:6 in Laemelli sample 
buffer which was then heat treated at 97°C for 10 minutes. An SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) of the samples was completed at 120 Volts for 75 minutes using an 
8% polyacrylamide gel (Invitrogen; Carlsbad, CA). Electroblot was then used at 125 Volts for 1 
hour to transfer the protein gel to a nitrocellulose membrane (Fischer Scientific; Hampton, NH). 
The membrane was blocked overnight using BAD at 4°C. In the morning, cell culture 
supernatant diluted 1:25 in BAD plus 0.1% Bovine Serum Albumin (BSA) and allowed to 
incubate for 2 hours at room temperature. The membrane was washed in PBST three separate 
times, each for 5 minutes. Then, a goat anti-mouse IR secondary antibody was diluted 1:5000 in 
BAD and was incubated at room temperature for 1 hour. The membrane was again washed in 
PBST three separate times, each for 5 minutes. Finally, chloro-1-naphol was used as the 
chromogenic substrate to detect the protein.  
Development of immunofluorescent assay for hybridoma screening 
 To develop an immunofluorescent assay for PRRSV MLVΔ23-S tag hybridoma screening, 
African green money kidney derived cells (MARC-145 cells) were seeded onto Immulon 1B 
medium binding 96 well micro-titer plates (Thermo Labsystems, Franklin, MA) and incubated 
for 48 hours. They were then infected with the PRRSV MLVD23S virus strain which was 
modified to contain the S-tag. The infected MARC-145 cells were incubated for 24 hours and 
then fixed with 80% acetone.  
 To screen hybridomas, 50 μL of undiluted cell culture supernatant was added to each 
well and then the plate was incubated with CO2 for 1 hour at 37°C. Next, the plate was washed 
three times with PBS and 100 μL of FITC (MP Bio; Santa Ana, CA) diluted PBS-BN + 1% Sodium 
Azide was added to each well. The plate was incubated for 1 hour at 37°C and then washed an 
additional three times with PBS. A few microliters of PBS were left in the bottom of each well 
after washing to ensure the cells did not dry out. The plate was then placed under an inverted 
microscope and UV light source to examine the cells for fluorescence.  
Development of mouse monoclonal antibodies 
 Using 250 μg of the purified NSP2 protein mixed with an equal volume of water-in-oil 
adjuvant (Seppic Montanide ISA 50 V2; Seppic, France), 3 ten-week-old specific pathogen-free 
mice were immunized intraperitoneally 4 times in three-week intervals. After the final 
immunization, the mice’s spleen cells were harvested and fused with NS-1 myeloma cells using 
50% polyethylene glycol (GIBCO, Grand Island, NY). They were then grown in the present of 
hypoxanthine-aminopterin-thymidine (HAT) media in order to select for only viable hybridoma 
clones. The cell culture supernatant was then screened using NSP2 S-tag ELISA and IFA to 
determine which clones produced antibodies specific to the PRRSV MLVΔ23-S tag antigen (as 
described in respective sections above). Those clones which were positive were then subcloned 
using limiting dilution in order to isolate monoclones. They were screened a final time using 
NSP2 S-tag ELISA, IFA, and Western blotting (as described in respective sections above). These 
monoclones were then isotyped using their culture fluids on a lateral-flow immunoglobulin 
typing kit (Serotec; Raleigh, NC).  
 
Development of rabbit polyclonal antisera 
 Two 4-month-old rabbits were immunized with a 150 μg dose of PRRSV NSP2 S-tag 
antigen mixed in an equal volume with water-in-oil adjuvant (Seppic Montanide; Seppic, 
France). The immunization was given both subcutaneously and intramuscularly in 4 separate 
locations. Immunization was repeated three times at three-week intervals. Rabbits were then 
euthanized, and their blood was collected via cardiac puncture. Their sera were tested via IFA, 
ELISA, and Western blot to determine if they had antibodies against PRRSV NSP2 S-tag.  
Animal studies were approved by the South Dakota State University Institutional Animal Care 
and Use Committee (17-066A Mice; 17-067A Rabbits). 
 
Results 
Expression of the PRRSV NSP2 S-tag protein 
 After running the PRRSV S-tag protein on a polyacrylamide gel, the gel was cut into two 
halves. The first half was stained using Coomassie blue (Figure 2B) while the second half 
underwent Western blotting (Figure 2A). The Coomassie blue staining allowed visualization of 
the proteins while Western blotting revealed the specificity of the PRRSV S-Tag protein, which 
contained a histidine label, to an anti-histidine monoclonal antibody. Overexpression of the 
protein was completed at a concentration of 1.5 mg/mL and showed a level of purification at 
90%. 
Development of mouse monoclonal antibodies 
 Initial screening of the PRRSV MLVΔ23-S tag hybridomas following the fusion resulted in 
6 primary wells. These primaries were cloned to limiting dilution and subclones underwent 
secondary screening via ELISA and IFA. Based on secondary screening, subclones were selected 
to be expanded. The final expanded clones were screened a final time via ELISA, IFA (Figure 3), 
and Western blotting (Figure 4). Each of the monoclones were also isotyped. All monoclones 
with an IgM isotype were positive via ELISA and Western blot but were negative via IFA. 
However, all of the IgG1 isotype monoclones were positive via ELISA, IFA, and Western blot. 
Compiled data involving isotype and reactivity to ELISA, IFA, and Western blot of 18 
monoclones is provided in Table 1.  
Development of rabbit polyclonal antisera 
 150 mL of whole blood was collected via cardiac stick from the two New Zealand Red 
rabbits after immunization with PRRSV NSP2 S-tag antigen. The blood was spun down then the 
serum (77 mL) was removed and titered using ELISA and IFA (Figure 4). The results of this titer 




































PRRSV MLVΔ23-S tag Monoclone 
Number 
Isotype Reactivity 
ELISA IFA Western Blot 
16-63 IgM + - + 
16-75 IgM + - + 
84-92 IgM + - + 
84-94 IgM + - + 
84-99 IgM + - + 
84-103 IgM + - + 
84-106 IgM + - + 
84-110 IgM + - + 
84-113 IgM + - + 
142-13-46 IgG1 + + + 
142-36-13 IgG1 + + + 
142-36-16 IgG1 + + + 
142-36-120 IgG1 + + + 
142-36-123 IgG1 + + + 
142-206-26 IgG1 + + + 
142-206-40 IgG1 + + + 
142-306-45 IgG1 + + + 
205-346 IgM + - + 
 
Table 1. Monoclonal antibody reactivity. Eighteen hybridoma clones. 
Immunoreactivity for each clone was tested via ELISA, IFA, and Western blotting. 
Clones which showed positive immunoreactivity are indicated by a “ + ” while those 
which were negative are indicated by a “ - ”.  
Rabbit serum-antibody titer determination 
(testing platform) 
Antibody Titer 
Rabbit A  
Antibody Titer 
Rabbit B 
IFA 1/1,200 1/1,600 
ELISA 1/10,000 1/12,000 
 
Table 2. PRRSV NSP2 S-tag rabbit antisera antibody titers. Sera collected from two 
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Figure 2. Western detection & Coomassie blue staining of PRRSV NSP2 S-tag 
protein. After protein purification, 100 μg of PRRSV NSP2 S-tag was run on a 
polyacrylamide gel using electrophoresis. Half of the gel underwent Western blotting 
(Figure 2A) while the other half was Coomassie blue stained (Figure 2B).  
 
 
Figure 3. Immunofluorescent staining of PRRSV MLVD23S -infected MARC-145 cells. 
Cell culture supernatant was taken from monoclones to stain infected MARC-145 



































Figure 4. Western blotting of PRRSV NSP2 S-tag protein. Six mouse monoclones 
were subjected to Western blot detection. All six were shown to recognize the 25 
kDa purified PRRSV NSP2 S-tag protein. Chromogenic (4-chloro-1-napthol) detection 
method was used after probing with a peroxidase-labeled, isotype-specific, anti-
mouse antibody.  
(M) Marker; (1) mAb 142-13-39 IgG1; (2) mAb 142-36-120 IgG1; (3) mAb 142-206-45 
IgG1; (4) mAb 205-346 IgM; (5) mAb 16-75 IgM; (6) mAb 84-99 IgM. 
1 2 3 4 5 6 M 
   
 
  
Figure 5. Immunofluorescent staining of PRRSV MLVD23S -infected MARC-145 
cells with rabbit polyclonal antisera. Rabbit A exhibited titers at 1/1200 while 
Rabbit B exhibited titers at 1/1600. 
Rabbit A Rabbit B 
Heterologous Rabbit Serum 
Control 
Rabbit B 400X 
Discussion 
 PRRSV has had a major economic effect on the swine industry since its emergence in the 
late 1980’s and early 1990’s [1].  It causes a significant reduction in the number of piglets which 
survive to weaning as well as an increase in secondary infections, reduction in growth 
efficiency, and even death in growing-finishing pigs. These losses combined are estimated to 
cost the swine industry around 560 million dollars annually [3]. A successful DIVA test 
(differentiating infected from vaccinated animals) will provide a tool necessary to move the 
industry one step closer to the eradication of PRRSV. Therefore, our primary objective of this 
study was to develop monoclonal and polyclonal antibodies which could be used in further 
research of a DIVA vaccine and accompanying diagnostic test.  
 We produced 18 mouse hybridoma monoclones against the PRRSV MLVΔ23-S tag 
antigen. These monoclones were isotyped and their immunoreactivity was tested via ELISA, IFA, 
and Western blot. All clones from the 142 series were IgG1 and immunoreactive via ELISA, IFA, 
and Western blot. Clones from the 16, 82, and 205 series were IgM and immunoreactive via 
ELISA and Western blot, but not IFA. This tells us that clones from the 142 series are able to 
detect both linear and conformational epitopes while clones from the 16, 82, and 205 series 
can only detect linear epitopes. In addition to the 18 monoclonal hybridoma clones, 75 mL of 
anti-PRRSV NSP2 S-tag rabbit polyclonal antisera was collected from two rabbits: Rabbit A and 
Rabbit B. It was tested via ELISA, IFA, and Western blot and found to have 1/1200 titers (Rabbit 
A) and 1/1600 titers (Rabbit B). 500 μL of recombinant/purified PRRSV NSP2 S-tag protein was 
also produced.  
 Purified PRRSV NSP2 S-tag protein can be used for future DIVA ELISA test development 
and can provide a positive control for future Western blot development. Both monoclonal and 
polyclonal antibodies can be used in future studies to validate DIVA IFA, ELISA, and Western 
blot assays or to develop a DIVA Fluorescent Microsphere Immunoassay (FMIA). 
 
Conclusion 
 The monoclonal and polyclonal antibodies produced in this study against PRRSV 
MLVΔ23-S tag antigen are currently being used as reagents in development of a DIVA test for 
PRRSV. A successful DIVA test for PRRSV could positively impact the swine industry and move us 
one step closer to the eradication of PRRSV.  
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